Results: Texture parameters were computed in the three perfusion maps and their 3D wavelet transforms, which resulted in 945 texture features defined for each of the two tumor sites. The discretization of images using set number of bins and setintervals gave the similar number of stable texture parameters (Table 1) . 40 parameters were correlated with tumor volume. Potentially standardizable factors introduced more variability into texture features than nonstandardizable. The highest variability was observed for pixel size. It caused instability in about 80% of parameters for both HN and lung tumors. Ten parameters were found to bestable in both HN and lung for potentially non-standardizable factors after thecorrection for inter-parameters correlations:
Material and Methods:
We reviewed medical records of patients with early stage HL diagnosed between January 2012 and December 2014 treated with standard combined modality therapy. 24 pre-treatment PET scans of the patients, acquired with a GE discovery STE, were selected for the analysis. A local nuclear medicine physician, blinded for the clinical outcome and interim PET (iPET) results, reviewed all PET scans. Volume of Interests (VOIs) were segmented employing cubes of volume 27 cm3 and 64 cm3 and centering them on the highest metabolic active mediastinic area. Texture analysis (TA) was applied through CGITA open source software and TA features correspondence with iPET results was assessed. Furthermore, we segmented isolated lymphnodes with a 40% of SUVmax isocontour algorithm. Each lymphnode was analyzed with TA as a "stand-alone patient" in order to increase the number of observations. TA features correspondence with iPET outcome of each lymphnode was assessed. Kruskall Wallis non-parametric test was employed to select most predictive features. Features, which showed prognostic power (or patient stratification ability), were employed to build Receiver Operating Curve (ROC) in order to score their sensibility and specificity.
Results: After iPET revision, 17 patiets were considered disease free after 2 cycles of ABVD whereas the remaining 7 patients had a positive iPET. Results obtained employing the 27 cm3 cubes showed that 4 features are able to predict iPET response with statistical significance (p<0.02) and a high efficiency up to 85% employing "uniformity feature". Using 64 cm3 cubes, we were able to isolate a feature named short zone emphasis, which has a discrimination sensibility of 100% with specificity 65% and indicates for ABVD resistant tumors the presence of short active zone in the surrounding of the mediastinic region highest metabolic active area. Lymphnode analysis showed that 5 out of 74 TA features could separate iPET responders and non-responders patients with statistical significance (p<0.01). In particular, "coarseness" feature has a discrimination efficiency of 73% (sensibility 77% and specificity 70%). Patients with lymphnodes that appear coarser have a higher probability of being positive at iPET.
Conclusion:
In this work we presented a method to predict early stage HL patient outcome and to quantitatively describe tumor morphology combining textural features. This method requires further validation in larger prospective study. 
EP-1865 DCE-CT lung tumour and aorta enhancement: is it an appropriate input vessel for kinetic modelling? M. La Fontaine

MAASTRO, Radiation Oncology, Maastricht, The Netherlands
Purpose or Objective: Dynamic contrast-enhanced Computed Tomography (DCE-CT) is a quantitative imaging modality to characterize heterogeneity in tumour vascularization. Problems in DCE-CT kinetic modelling have been reported due to lung tumour enhancement arriving prior to aortal enhancement. Studies have attempted to correct the issue by shifting the enhancement curve in time, segmenting different input vessels and/or dual-input kinetic modelling. The purpose of this project was to develop a methodology for a detailed spatio-temporal analysis of the heterogeneous lung tumour enhancement for the purpose of applying different input vessels in kinetic modelling.
Material and Methods: Nine patients with non-small cell lung cancer (NSCLC) received DCE-CT scans (Siemens Definition
Flash) prior to radiation therapy using shuttle mode acquisition with a longitudinal FOV of 13 cm. The DCE-CT scans were first motion corrected (Siemens VPCT) and subsequently, the primary lung tumour was contoured by a radiation oncologist. Using an in-house model, tumour and aorta time attenuation curves were analysed by gammavariate function fitting. The arrival time of the contrast agent was estimated by a threshold of 1% of the maximum enhancement of the fit. To determine the percentage of tumour enhancement prior and after aortic enhancement, the arrival times of the gamma-variate fit of the tumour and aorta were compared. Tumour voxels were considered acausal if the arrival time was greater than 2 s before the S880 ESTRO 35 2016 _____________________________________________________________________________________________________ aorta arrival time, to correct for acquisition time differences and fitting uncertainties.
Results: Gamma-variate fitting was able to capture contrast arrival time in the DCE-CT images for all 9 patients. Two of the patients displayed clear tumour enhancement prior to aortal enhancement. For these patients, the percentage of the tumour with acausal enhancement with/without a 2 s allowance was 64%/73% and 37%/54%. The mean and standard deviation of the enhancement time differences between the tumour voxels with acausal enhancement and the aorta with/without a 2 sec allowance were -1.8 s ± 0.6 s/-3.4 s ± 1.1 s, and -1.4 ± 0.6 s/-2.6 ± 1.3 s, for each patient.
Conclusion:
Our study found apparent acausal enhancement in lung tumours in relation to the aorta for a subset (22%) of the NSCLC patient population examined. For these patients, gamma-variate fitting was able to determine both the percentage of the tumour with acausal enhancement times and the effective enhancement time difference between the tumour voxels and the aorta. These findings highlight the tumor vascular heterogeneity and warrant new kinetic analysis models to incorporate different tumor enhancement analysis and the selection of an appropriate input function.
EP-1866 Traceable calibration chain of PET/CT scanners for I-124
L. Joulaeizadeh 1 VSL, Ionizing Radiation, Delft, The Netherlands 1 Purpose or Objective: PET scanners are used for several decades in a wide range of diagnostic experiments. In the treatment of thyroid cancer with I-131, quantitative information of a PET scan using I-124 is used to determine the release dose to the tumor and critical organs during the treatment. To guarantee comparison of absolute quantification among institutes, measurements have to come along with uncertainty estimates and have to be traceable (i.e. linked) to international measurement standards. However, despite recent advances, PET/CT calibrations are not traceable to any measurement standard. As a result, scans taken at different scanners are not or hardly comparable with each other.
Material and Methods: VSL (National Metrology Institute in
The Netherlands) maintains and develops the national measurement standards, and is able to supply support to the development of calibration chains and standard measurement protocols, thereby guaranteeing traceability to internationally accepted measurement standards. The purpose of this project is to develop a metrological infrastructure and service for on-site calibration of PET/CT scanners. VSL has the facilities to measure the activity of radionuclide solutions in a secondary level traceable to the primary standard at NPL (National Metrology Institute in UK). In 2012 and 2013 in the context of a large national multicenter trial (19 hospitals), a hospital in The Netherlands has performed non-traceable inter-comparison for I-124.
Traceable measurements to validate concept method have been performed by VSL in 2015 for few scanners in The Netherlands. A cylindrical PMMA phantom including 6 holes to position vials of I-124 has been used. Activities inside the vials have been standardized using the secondary standard at VSL with an uncertainty in the range of 2.5% (k=2). Then the phantom has been measured in different scanners.
Results:
The results show differences between the measured activities in two setups which is typically around 40% for activities around 1 MBq, however goes rapidly high by lowering the activity.
Conclusion: PET/CT calibrations for I-124 are not traceable to any measurement standard. The reason is lack of any calibration chain and protocol. Calibration measurements have been introduced and examined for few PET/CT scanners. The results of these measurements strongly propose the need of traceable calibration chain. 
EP-1867 Dosimetric comparison between jaw tracking and static jaw modes in volumetric
Material and Methods:
The dose distribution around critical organs close to the tumor in HCC is critical owing to its high fractionation dose in Stereotactic Body Radiation Therapy (SBRT). Varian TrueBeam™ (Varian Medical Systems) system provides the JT technique, which keeps the main jaws of the LINAC dynamically as close as possible to the MLC aperture during dose delivery, hence minimize the leakage and transmission of the MLC and further reduces the dose to the organ at risk (OAR). In order to validate the advantage of OAR dose sparing by using JT technique in SBRT for HCC, treatment plans using JT and nJT techniques were designed for dosimetric comparison. Fifteen HCC patients were selected, all treated with doses of 50 Gy in 5 daily fractions with VMAT using 10 MV FFF beams. The maximum dose rate enabled for FFF beams is 2400 MU/min for 10 MV. Each VMAT plan was individually designed using two full and one partial arcs with collimator rotation of 30 and 330 ˚ to obtain the best adherence to planning objectives for each patient. All dose distributions were computed with the Analytical Anisotropic Algorithm (AAA, version 13.6) implemented in the Eclipse planning system with a calculation grid resolution of 2.5 mm. Planning objectives to target coverage aimed to cover CTV with 100% and PTV with at least 95% of the prescribed dose. The main OARs considered were: spinal cord, kidneys, stomach, duodenum, small bowel, chest wall and liver. JT and nJT Planning were performed with the same objectives constraint while plan optimization and the mean doses of OARs were obtained for plan comparison.
Results: At the same CTV and PTV dose coverage, every comparative result shows that JT plan did lower the dose received by OAR and improve the dose fall-off around the low dose region. The significant OAR dose reduction for the JT plan in this study are as follows: the mean doses to the liver was 130cGy less, the V15 of liver was 100 c.c. smaller, the maximum spinal cord dose was 300 cGy lower, and the mean kidney dose was 200 cGy lower than that in the nJT plan.
Conclusion: JT technique did show superior OARs sparing than nJT plans in HCC. The dose reduction is of clinical importance, especially for high fractionation dose SBRT treatment.
